(Q36101134)

12 August 2017

1 reference

title

Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies (English)

1 reference

12 August 2017

2

Gordon Dougan

1 reference

12 August 2017

Frank R Brennan

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

23

1 reference

12 August 2017

issue

24

1 reference

12 August 2017

page(s)

3210-3222

1 reference

Intussusception among infants given an oral rotavirus vaccine

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Vaccination and autoimmune disease: what is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Immunopathogenesis of vaccine-enhanced RSV disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

New technologies for making vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Vaccine adjuvant technology: from mechanistic concepts to practical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Virus-based vectors for human vaccine applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Cowpea mosaic virus as a vaccine carrier of heterologous antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

7 January 2021

Novel adjuvant systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

The development and use of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

GM-CSF-based cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Design and selection of vaccine adjuvants: animal models and human trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Genetically modified tumour vaccines--where we are today.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

DNA-based vaccines for allergic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Non-clinical vaccine safety assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

From genome to vaccine: in silico predictions, ex vivo verification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Allergenic components of vaccines and avoidance of vaccination-related adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Tools of the trade in vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Computers aid vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Production, purification and analysis of an experimental DNA vaccine against rabies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Optimized expression and specific activity of IL-12 by directed molecular evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Vaccines: predicting the risk of allergy and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Leukemia case triggers tighter gene-therapy controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Potential DNA vaccine integration into host cell genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Histopathologic approaches to detect changes indicative of immunotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Immunotoxicity testing in the rat: an improved multiple assay model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

A local lymph node assay to analyse immunosuppressive effects of topically applied drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Cynomolgus monkeys (Macaca fascicularis) in preclinical immune function safety testing: development of a delayed-type hypersensitivity procedure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Acute and subchronic immunotoxicity of p-chloronitrobenzene in mice. I. Effect on natural killer, cytotoxic T-lymphocyte activities and mitogen-stimulated lymphocyte proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Repeated administration of whole-cell and acellular pertussis vaccines affects haemodynamics and autonomic responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Reproductive toxicity testing of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Immunological relationship between the mother and the fetus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Th1-type immunity is incompatible with successful pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Maternal immunization with inactivated influenza vaccine: rationale and experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Placental transport of immunoglobulin G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Maternal immunization: US FDA regulatory considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Reproductive/developmental toxicity and immunotoxicity assessment in the nonhuman primate model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Reproductive toxicology studies and immunotherapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.072

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.11.072

1 reference

12 August 2017

1 reference